Payment overview · 2025
General Payments
$483.42
23 reported records · 10 companies
Healthcare provider profile · identity verified
Shujauddin Khan, M.D.
Allopathic & Osteopathic Physicians|General Practice · SANDSTON, VA · NPI 1114126067
Verified facts
What the public records show
CMS Open Payments records show Shujauddin Khan, M.D. received $483.42 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.05 | 31.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $109.77 | 22.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.52 | 9.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.62 | 8.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.74 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.58 | 5.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.41 | 4.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.77 | 4.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $19.86 | 4.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.10 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $483.42 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $109.77 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $109.77 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $109.77 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.81 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $70.24 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $17.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 312 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 57 |
| Lisinopril | Lisinopril | 207 | 53 |
| Metformin Hcl | Metformin Hcl | 163 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 35 |
| Gabapentin | Gabapentin | 114 | 35 |
| Potassium Chloride | Potassium Chloride | 114 | 35 |
| Alprazolam | Alprazolam | 113 | 30 |
| Furosemide | Furosemide | 106 | 32 |
| Losartan Potassium | Losartan Potassium | 96 | 25 |
| Omeprazole | Omeprazole | 90 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 29 |
| Tramadol Hcl | Tramadol Hcl | 83 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 20 |
| Prednisone | Prednisone | 76 | 43 |
| Allopurinol | Allopurinol | 74 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 22 |
| Mounjaro | Tirzepatide | 72 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 18 |
| Simvastatin | Simvastatin | 68 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 13 |
| Ozempic | Semaglutide | 62 | 15 |
| Celecoxib | Celecoxib | 60 | 16 |
| Azithromycin | Azithromycin | 59 | 51 |
| Meloxicam | Meloxicam | 58 | 18 |
| Bupropion Xl | Bupropion Hcl | 57 | 17 |
| Lovastatin | Lovastatin | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | 16 |
| Spironolactone | Spironolactone | 55 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Clonazepam | Clonazepam | 50 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Carvedilol | Carvedilol | 42 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 11 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Famotidine | Famotidine | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 11 |
| Eliquis | Apixaban | 28 | 11 |
| Finasteride | Finasteride | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | 11 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Fluconazole | Fluconazole | 14 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Pifeltro | Doravirine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Welchol | Colesevelam Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $483.42 · 23 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, DUPIXENT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FARXIGA, Fluad, Flucelvax, MOUNJARO, OPSUMIT, Ozempic, PREVNAR 20, UPTRAVI, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error